Announcement of Quarterly and Annual Results for the Financial year ended on 31.03.2026
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Kidney and Super Speciality Ltd reported standalone revenue of Rs 4,010.02 Lacs (up 14% YoY) and consolidated revenue of Rs 8,201.34 Lacs (up 104% YoY) for FY2026. The significant consolidated growth is largely driven by acquisitions of multiple subsidiary entities (7 subsidiaries/firms). Standalone PAT grew 8.7% to Rs 990.14 Lacs while consolidated PAT rose 77% to Rs 1,681.18 Lacs. However, operating cash flows turned negative: standalone at Rs -745.86 Lacs (vs Rs 1,535.56 Lacs profit in FY2025) and consolidated at Rs -386.17 Lacs (vs Rs 1,360.80 Lacs in FY2025). The company raised Rs 25,080 Lacs via equity issuance but spent heavily on acquisitions (Rs 8,360 Lacs goodwill) and capital advances (Rs 5,900 Lacs). Auditor issued unmodified reports with no qualifications.
Strong revenue and PAT growth on consolidated basis signals successful integration of acquired subsidiaries, but negative operating cash flows despite profitability raises concerns about earnings quality and working capital management. Investors should monitor cash conversion going forward.